COLL at a glance
COLLEGIUM PHARMACEUTICAL, INC (COLL, SEC CIK 1267565) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as June 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), COLLEGIUM PHARMACEUTICAL, INC (COLL) reported revenue of $780.6 million (up 23.6% from FY2024) and net income of $62.9 million. Diluted EPS was $1.73.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding COLLEGIUM PHARMACEUTICAL, INC (COLL) shares worth $690.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Freund John Gordon on May 18, 2026 of 20 shares at $34.05 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $780.6M
- +23.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 32 funds
- $690.2M · +0 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Commercializes differentiated biopharmaceutical products for ADHD and moderate to severe pain in the U.S.
- New: September 2024 acquisition of Ironshore adds Jornay PM, expanding into neuropsychiatry and ADHD market
- Strategic shift: Diversification beyond pain management to ADHD stimulation therapy with Jornay PM launch
- Quantitative: Pain sales force ~105 reps; ADHD sales force ~200 reps targeting ~21,000 prescribers
- Noteworthy: FDA granted pediatric exclusivity extensions up to January 2027 for Nucynta IR and December 2025 for Nucynta ER
Risk Factors
- Cybersecurity risks overseen by Audit Committee with quarterly updates from Head of IT on incidents and infrastructure vulnerabilities
- Potential impact from cybersecurity incidents managed by Head of IT with 20+ years experience and senior leadership for 10+ years
- Operational risk from information technology infrastructure reliant on bi-weekly management meetings and established incident response plan
Management Discussion & Analysis
- Revenue $780.6M in 2025, up $149.2M YoY from $631.4M; Jornay PM +$111.7M, Nucynta Products +$19.8M, Belbuca +$10.4M, Xtampza ER +$8.0M
- Gross profit $463.3M vs $377.3M; operating expenses $284.8M vs $210.4M; operating income $179.6M vs $169.9M; operating margin ~23.0% vs ~26.9% (calculated from operating income/revenue)
- Best segment: Jornay PM revenue $111.7M increase due to full year revenue in 2025 post-acquisition; worst: Symproic revenue down $0.7M
- Cash & equivalents $231.3M at 2025 year-end vs $70.6M at 2024; 2025 Term Loan $580M outstanding with $29M due next 12 months; no detailed capex, buyback or dividend info provided
- Management expects cash, cash equivalents, marketable securities plus operations to fund expenses, debt service, capex; risks include generic launch of Nucynta IR and ER impacting revenues
AI summary of the COLL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $199.9M vs $188.0M, up $11.9M YoY
- Net loss $15.1M vs net income $12.0M; operating margin 1.9% vs 18.7%
- Best performer Jornay PM, revenue up $13.4M; worst Nucynta Products, revenue down $11.1M
- Cash $129.5M; operating cash flow $128.4M for six months vs $127.8M
- Azstarys acquisition consumed $655.4M cash; management expects liquidity to fund operations for the foreseeable future
Risk Factors
- Newly triggered FDA labeling changes following July 31, 2025 opioid safety announcement, including dosing, discontinuation, overdose, and interaction warnings
- Most materially updated promotional-compliance risk following September 2025 FDA scrutiny and numerous warning letters targeting allegedly misleading pharmaceutical advertising
- Regulatory risk from mandatory Opioid Analgesic REMS, with FDA modifications potentially increasing commercialization costs and reducing prescribing
- Near-term operational risk from heightened competition, generic approvals, and physician or payer acceptance affecting product sales
- Financial risk from $865.5 million term loan, $241.5 million convertible notes, and unhedged floating-rate SOFR exposure
AI summary of the COLL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- $50 million ASR with Jefferies, representing part of the $150 million repurchase program authorized in July 2025
- Initial delivery of 1,556,420 shares, approximately 80% of expected ASR shares
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 6, 2026 and furnished as Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Earnings presentation released August 6, 2026 under Regulation FD
- Exhibit 99.2 contains management’s earnings-related information and investor materials
Item EX-99.1: Item EX-99.1
- Q2 product revenue $199.9M, up 6% YoY; JORNAY PM revenue $46.1M, up 41%, supporting ADHD growth thesis
- AZSTARYS acquisition contributed $12.9M from May 12 and lifted full-year guidance to $65–$75M
Item EX-99.1: Item EX-99.1
- Going-concern warning: recurring losses, net capital deficiency, and funding needs create substantial doubt within 12 months
- 2025 product sales increased to $113.6M from $79.6M, but operating cash flow remained negative at $105.0M
AI summaries of COLL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for COLL
Don't miss the next COLL filing
- Alerts as it files. A push when COLL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut COLL, by share count.
- Ask anything. An AI agent that reads every COLL filing and answers with sources.
COLL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SANTINI GINO | M | Jun 8, 2026 | 8,700 | - |
| SANTINI GINO | M | Jun 8, 2026 | 8,700 | $16.49 |
| Freund John Gordon | Sell | May 18, 2026 | 20 | $34.05 |
| Freund John Gordon | M | May 15, 2026 | 8,700 | - |
| Freund John Gordon | M | May 15, 2026 | 8,700 | $16.49 |
| Freund John Gordon | Sell | May 15, 2026 | 4,127 | $34.54 |
| SANTINI GINO | A | May 14, 2026 | 8,741 | - |
| Lurker Nancy | A | May 14, 2026 | 8,741 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $566.8M | $631.4M | $780.6M |
| Gross Profit | - | $377.3M | $463.3M |
| Operating Income | - | $169.9M | $179.6M |
| Net Income | - | $69.2M | $62.9M |
| Gross Margin | - | 59.8% | 59.3% |
| Op. Margin | - | 26.9% | 23.0% |
| Net Margin | - | 11.0% | 8.1% |
| Balance Sheet | |||
| Total Assets | - | $1.7B | $1.7B |
| Equity | $195.4M | $228.8M | $301.7M |
| ROE | - | 30.2% | 20.8% |
| Per Share | |||
| EPS | - | $1.86 | $1.73 |
| Cash Flow | |||
| Operating CF | - | $205.0M | $329.3M |
| CapEx | - | $1.7M | $1.7M |
Source: XBRL data in COLLEGIUM PHARMACEUTICAL, INC (COLL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate COLL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $690.2M |
| Q1 2026 | 32 | $606.1M |
| Q4 2025 | 30 | $813.1M |
| Q3 2025 | 29 | $633.4M |
| Q2 2025 | 29 | $521.3M |
| Q1 2025 | 26 | $394.7M |
| Q4 2024 | 22 | $336.5M |
| Q3 2024 | 19 | $351.6M |
- Millennium Management+376.1K (+104%)
- Principal Financial Group+337.3K (+26%)
- BlackRock+307.2K (+6%)
- Invesco Ltd+290.6K (+18%)
- State Street Corp+104.3K (+7%)
- Two Sigma Investments−483.4K (-82%)
- D.E. Shaw & Co−192.3K (-36%)
- Renaissance Technologies LLC−102.9K (-7%)
- Citadel Advisors LLC−52.8K (-43%)
- JPMorgan Chase & Co−39.6K (-36%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 219 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
COLL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 24, 2026 | - | - | |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 5, 2026 | - | - | |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 15, 2026 | - | Analysis | |
| 4 | May 13, 2026 | - | - | |
| SC 13G | May 12, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| SC 13G | May 8, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
COLL SEC filings: frequently asked questions
Which institutions hold COLL stock?
As of June 30, 2026, the largest COLLEGIUM PHARMACEUTICAL, INC (COLL) holders among the 13F filers tracked by SignalX were BlackRock ($197.0 million), Invesco Ltd ($68.1 million), Principal Financial Group ($59.1 million), State Street Corp ($55.3 million), Vanguard Capital Management LLC ($50.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was COLL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), COLLEGIUM PHARMACEUTICAL, INC (COLL) reported revenue of $780.6 million (up 23.6% from FY2024) and net income of $62.9 million. Diluted EPS was $1.73. The figures come from the XBRL data in the 10-K.
What are the main risks in COLL's latest 10-K?
In the 10-K filed February 26, 2026, COLLEGIUM PHARMACEUTICAL, INC (COLL) flagged: Cybersecurity risks overseen by Audit Committee with quarterly updates from Head of IT on incidents and infrastructure vulnerabilities. Potential impact from cybersecurity incidents managed by Head of IT with 20+ years experience and senior leadership for 10+ years. (AI summary of the Risk Factors section.)
What did COLL report in its latest 8-K?
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K on August 13, 2026 reporting Item 8.01 (Other Events). $50 million ASR with Jefferies, representing part of the $150 million repurchase program authorized in July 2025.
What are the latest COLL SEC filings?
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on June 10, 2026.
What is COLL's SEC CIK number?
COLLEGIUM PHARMACEUTICAL, INC (COLL)'s SEC Central Index Key (CIK) is 1267565. EDGAR lists every COLL filing under that number.
Ask anything about COLL
The research agent reads COLL's filings, financials, insider trades and 13F holders, then answers with sources.